ES2545094T3 - Sistema terapéutico transdérmico para la administración de un principio activo - Google Patents
Sistema terapéutico transdérmico para la administración de un principio activo Download PDFInfo
- Publication number
- ES2545094T3 ES2545094T3 ES10194968.3T ES10194968T ES2545094T3 ES 2545094 T3 ES2545094 T3 ES 2545094T3 ES 10194968 T ES10194968 T ES 10194968T ES 2545094 T3 ES2545094 T3 ES 2545094T3
- Authority
- ES
- Spain
- Prior art keywords
- layer
- rivastigmine
- imp
- adhesive
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013543 active substance Substances 0.000 title abstract description 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000010410 layer Substances 0.000 abstract description 41
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical group CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 abstract description 40
- 229960004136 rivastigmine Drugs 0.000 abstract description 35
- 229920000642 polymer Polymers 0.000 abstract description 33
- 239000004480 active ingredient Substances 0.000 abstract description 30
- 239000012528 membrane Substances 0.000 abstract description 29
- 239000000203 mixture Substances 0.000 abstract description 29
- 239000011159 matrix material Substances 0.000 abstract description 26
- 239000012790 adhesive layer Substances 0.000 abstract description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 18
- 229920002367 Polyisobutene Polymers 0.000 abstract description 17
- 239000000853 adhesive Substances 0.000 abstract description 10
- 230000001070 adhesive effect Effects 0.000 abstract description 10
- 239000004821 Contact adhesive Substances 0.000 abstract description 8
- 229920001083 polybutene Polymers 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 description 19
- 229920000058 polyacrylate Polymers 0.000 description 19
- 238000009472 formulation Methods 0.000 description 15
- -1 polypropylene Polymers 0.000 description 13
- 239000004698 Polyethylene Substances 0.000 description 11
- 229920000573 polyethylene Polymers 0.000 description 11
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 239000000178 monomer Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 5
- 230000001427 coherent effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229940108366 exelon Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920005987 OPPANOL® Polymers 0.000 description 4
- 229920002399 Oppanol® B 10 SFN Polymers 0.000 description 4
- 229920002461 Oppanol® B 50 SF Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- LMAUULKNZLEMGN-UHFFFAOYSA-N 1-ethyl-3,5-dimethylbenzene Chemical compound CCC1=CC(C)=CC(C)=C1 LMAUULKNZLEMGN-UHFFFAOYSA-N 0.000 description 3
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 3
- RUMACXVDVNRZJZ-UHFFFAOYSA-N 2-methylpropyl 2-methylprop-2-enoate Chemical compound CC(C)COC(=O)C(C)=C RUMACXVDVNRZJZ-UHFFFAOYSA-N 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- IAXXETNIOYFMLW-COPLHBTASA-N [(1s,3s,4s)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-methylprop-2-enoate Chemical compound C1C[C@]2(C)[C@@H](OC(=O)C(=C)C)C[C@H]1C2(C)C IAXXETNIOYFMLW-COPLHBTASA-N 0.000 description 3
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 3
- OIWOHHBRDFKZNC-UHFFFAOYSA-N cyclohexyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1CCCCC1 OIWOHHBRDFKZNC-UHFFFAOYSA-N 0.000 description 3
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229940119545 isobornyl methacrylate Drugs 0.000 description 3
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- BOQSSGDQNWEFSX-UHFFFAOYSA-N propan-2-yl 2-methylprop-2-enoate Chemical compound CC(C)OC(=O)C(C)=C BOQSSGDQNWEFSX-UHFFFAOYSA-N 0.000 description 3
- LYBIZMNPXTXVMV-UHFFFAOYSA-N propan-2-yl prop-2-enoate Chemical compound CC(C)OC(=O)C=C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013148 permeation assay Methods 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10194968.3A EP2468274B1 (de) | 2010-12-14 | 2010-12-14 | Transdermales therapeutisches System zur Verabreichung eines Wirkstoffs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2545094T3 true ES2545094T3 (es) | 2015-09-08 |
Family
ID=43836835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10194968.3T Active ES2545094T3 (es) | 2010-12-14 | 2010-12-14 | Sistema terapéutico transdérmico para la administración de un principio activo |
| ES11799413T Active ES2836483T3 (es) | 2010-12-14 | 2011-12-14 | Sistema terapéutico transdérmico para la administración de un principio activo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11799413T Active ES2836483T3 (es) | 2010-12-14 | 2011-12-14 | Sistema terapéutico transdérmico para la administración de un principio activo |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10660863B2 (enExample) |
| EP (2) | EP2468274B1 (enExample) |
| JP (1) | JP6043296B2 (enExample) |
| KR (1) | KR101842309B1 (enExample) |
| CN (3) | CN103269698B (enExample) |
| AU (2) | AU2011343363B2 (enExample) |
| BR (1) | BR112013014616B1 (enExample) |
| CA (2) | CA3065240C (enExample) |
| CY (2) | CY1116638T1 (enExample) |
| DK (2) | DK2468274T3 (enExample) |
| EA (1) | EA026520B1 (enExample) |
| ES (2) | ES2545094T3 (enExample) |
| HK (1) | HK1243336A1 (enExample) |
| HR (2) | HRP20201880T1 (enExample) |
| HU (2) | HUE027916T2 (enExample) |
| LT (1) | LT2651410T (enExample) |
| MX (1) | MX345344B (enExample) |
| MY (1) | MY183873A (enExample) |
| PL (2) | PL2468274T3 (enExample) |
| PT (2) | PT2468274E (enExample) |
| RS (2) | RS54173B1 (enExample) |
| SI (2) | SI2468274T1 (enExample) |
| SM (2) | SMT202000638T1 (enExample) |
| WO (1) | WO2012080365A1 (enExample) |
| ZA (1) | ZA201303965B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012000369A1 (de) * | 2012-01-11 | 2013-07-11 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System mit Cholinesterase-Hemmer |
| DE102012016317A1 (de) * | 2012-08-14 | 2014-02-20 | Jenabatteries GmbH | Redox-Flow-Zelle zur Speicherung elektrischer Energie |
| US20150196515A1 (en) * | 2012-08-15 | 2015-07-16 | Dow Coming Corporation | Multi-Layer Drug Delivery System |
| WO2014111790A2 (en) * | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
| US20240082065A1 (en) * | 2016-07-08 | 2024-03-14 | Moteah Williams | Waterproof and transparent wound barrier and method of manufacturing same |
| EP3501518B1 (en) | 2016-08-22 | 2025-05-14 | Kyukyu Pharmaceutical Co., Ltd. | Transdermal patch of rivastigmine |
| JP7193863B2 (ja) * | 2017-07-19 | 2022-12-21 | 帝國製薬株式会社 | リバスチグミン含有経皮吸収型製剤 |
| DE102018120506A1 (de) * | 2017-10-20 | 2019-04-25 | Amw Gmbh | Stabilisiertes transdermales Darreichungssystem |
| DE102017127433A1 (de) * | 2017-11-21 | 2019-05-23 | Lts Lohmann Therapie-Systeme Ag | TTS auf Basis von klebenden Weichmacher-Polymer-Matrices |
| CN111971032A (zh) * | 2018-03-13 | 2020-11-20 | 罗曼治疗系统股份公司 | 包含有机硅丙烯酸杂化聚合物的透皮治疗系统 |
| JP7170285B2 (ja) * | 2018-05-17 | 2022-11-14 | パナソニックＩｐマネジメント株式会社 | 生体貼付け用選択透過膜、経皮吸収キットおよび美容方法 |
| ES2923891T3 (es) | 2018-08-08 | 2022-10-03 | Danapak Flexibles As | Películas y láminas mejoradas para usarse en el envase de compuestos reactivos |
| KR102823139B1 (ko) | 2018-08-31 | 2025-06-19 | 에스케이케미칼 주식회사 | 장기 투여용 리바스티그민 패취 |
| KR102710072B1 (ko) | 2018-08-31 | 2024-09-24 | 에스케이케미칼 주식회사 | 장기 투여용 리바스티그민 패취 |
| EP3996693A1 (en) * | 2019-07-09 | 2022-05-18 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system comprising an active agent-containing layer comprising an acrylic polymer and a skin contact layer comprising a silicone gel adhesive |
| CN113616625B (zh) * | 2021-08-26 | 2023-05-30 | 大连科翔科技开发有限公司 | 一种卡巴拉汀的长效透皮贴剂 |
| DE102021128912A1 (de) * | 2021-11-05 | 2023-05-11 | Lts Lohmann Therapie-Systeme Ag. | Okklusives pflaster mit flexibler backing |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
| CA2142871A1 (en) * | 1992-08-25 | 1994-03-03 | Jesus Miranda | Printed transdermal drug delivery device |
| JPH0912448A (ja) * | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
| GB9800526D0 (en) | 1998-01-12 | 1998-03-11 | Ciba Geigy Ag | Organic compounds |
| US6348210B1 (en) * | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| DE19918106A1 (de) | 1999-04-22 | 2000-10-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern |
| DE10033853A1 (de) | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| DE10103860B4 (de) * | 2001-01-30 | 2004-12-23 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung |
| DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| DE10141652B4 (de) | 2001-08-24 | 2011-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung |
| PL2216018T3 (pl) * | 2004-10-21 | 2012-09-28 | Durect Corp | Transdermalne systemy dostarczania |
| US8252319B2 (en) * | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| CN101351233A (zh) * | 2005-12-30 | 2009-01-21 | 科洛普拉斯特公司 | 具有可塑的层作为皮肤接触表面的层状粘合构造 |
| CN101304735A (zh) * | 2006-01-12 | 2008-11-12 | Lts勒曼治疗系统股份公司 | 用于挥发性和/或热不稳定的物质的经皮治疗体系 |
| CN101460156B (zh) * | 2006-05-08 | 2011-06-08 | 帝国制药株式会社 | 抗痴呆药的经皮吸收制剂 |
| US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
| EP2167001A4 (en) | 2007-07-10 | 2012-10-31 | Agile Therapeutics Inc | DEVICE FOR THE DERIVED ULTRASONIC WELDING |
| WO2009026135A2 (en) * | 2007-08-17 | 2009-02-26 | Alza Corporation | Controlled transdermal bisoprolol delivery system |
| WO2009107478A1 (ja) * | 2008-02-27 | 2009-09-03 | 久光製薬株式会社 | 貼付剤及び包装体 |
| US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
| JP2010126450A (ja) * | 2008-11-25 | 2010-06-10 | Lintec Corp | 経皮吸収貼付剤 |
| DK2515886T3 (en) * | 2009-12-22 | 2018-06-14 | Luye Pharma Ag | Transdermal therapeutic system for administration of rivastigmine or derivatives thereof |
-
2010
- 2010-12-14 EP EP10194968.3A patent/EP2468274B1/de active Active
- 2010-12-14 DK DK10194968.3T patent/DK2468274T3/en active
- 2010-12-14 PL PL10194968T patent/PL2468274T3/pl unknown
- 2010-12-14 HU HUE10194968A patent/HUE027916T2/en unknown
- 2010-12-14 SI SI201031006T patent/SI2468274T1/sl unknown
- 2010-12-14 ES ES10194968.3T patent/ES2545094T3/es active Active
- 2010-12-14 PT PT101949683T patent/PT2468274E/pt unknown
- 2010-12-14 RS RS20150562A patent/RS54173B1/sr unknown
-
2011
- 2011-12-14 MX MX2013005581A patent/MX345344B/es active IP Right Grant
- 2011-12-14 EA EA201300704A patent/EA026520B1/ru not_active IP Right Cessation
- 2011-12-14 LT LTEP11799413.7T patent/LT2651410T/lt unknown
- 2011-12-14 HU HUE11799413A patent/HUE052137T2/hu unknown
- 2011-12-14 HR HRP20201880TT patent/HRP20201880T1/hr unknown
- 2011-12-14 JP JP2013543774A patent/JP6043296B2/ja active Active
- 2011-12-14 CA CA3065240A patent/CA3065240C/en active Active
- 2011-12-14 WO PCT/EP2011/072812 patent/WO2012080365A1/de not_active Ceased
- 2011-12-14 US US13/994,242 patent/US10660863B2/en active Active
- 2011-12-14 DK DK11799413.7T patent/DK2651410T3/da active
- 2011-12-14 CN CN201180059614.1A patent/CN103269698B/zh active Active
- 2011-12-14 KR KR1020137016047A patent/KR101842309B1/ko active Active
- 2011-12-14 RS RS20201478A patent/RS61155B1/sr unknown
- 2011-12-14 CN CN202110438860.3A patent/CN113244199A/zh active Pending
- 2011-12-14 MY MYPI2013001975A patent/MY183873A/en unknown
- 2011-12-14 SM SM20200638T patent/SMT202000638T1/it unknown
- 2011-12-14 EP EP11799413.7A patent/EP2651410B1/de active Active
- 2011-12-14 CN CN201710451001.1A patent/CN107412202A/zh active Pending
- 2011-12-14 SI SI201131933T patent/SI2651410T1/sl unknown
- 2011-12-14 AU AU2011343363A patent/AU2011343363B2/en active Active
- 2011-12-14 ES ES11799413T patent/ES2836483T3/es active Active
- 2011-12-14 PL PL11799413T patent/PL2651410T3/pl unknown
- 2011-12-14 PT PT117994137T patent/PT2651410T/pt unknown
- 2011-12-14 BR BR112013014616-8A patent/BR112013014616B1/pt active IP Right Grant
- 2011-12-14 CA CA2817461A patent/CA2817461C/en active Active
-
2013
- 2013-05-30 ZA ZA2013/03965A patent/ZA201303965B/en unknown
-
2015
- 2015-07-31 SM SM201500184T patent/SMT201500184B/xx unknown
- 2015-08-19 HR HRP20150881TT patent/HRP20150881T1/hr unknown
- 2015-08-25 CY CY20151100738T patent/CY1116638T1/el unknown
-
2017
- 2017-08-11 AU AU2017213569A patent/AU2017213569B2/en active Active
-
2018
- 2018-02-28 HK HK18102858.7A patent/HK1243336A1/zh unknown
-
2020
- 2020-04-28 US US16/860,210 patent/US20200289426A1/en not_active Abandoned
- 2020-11-25 CY CY20201101121T patent/CY1123712T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545094T3 (es) | Sistema terapéutico transdérmico para la administración de un principio activo | |
| ES2670227T3 (es) | Sistema terapéutico transdérmico para la administración de rivastigmina o sus derivados | |
| CA3031945C (en) | TRANSDERMAL FORMULATION AND METHOD OF ADMINISTRATING A NON-IONIZED, LOW-SOLUBILITY OR UNSTABLE, NEUTRAL-FORMED DRUG BY ON-SITE SALT CONVERSION OF A NEUTRAL-FORMED DRUG TO A SALT-FORM | |
| US9585862B2 (en) | Patch containing rivastigmine | |
| PT1418894E (pt) | Sistema terapêutico transdérmico com fentanil ou substâncias análogas. | |
| BR112019027037B1 (pt) | Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema | |
| EP2614819A1 (en) | Percutaneous absorbent and adhesive sheet for skin patch | |
| ES2993032T3 (en) | Adhesive polymer and medical adhesive patch | |
| ES2897696T3 (es) | Hoja adhesiva para aplicación sobre la piel y preparación de absorción percutánea que utiliza la misma | |
| US20150209302A1 (en) | Adhesive skin patch | |
| KR20120130073A (ko) | 리바스티그민 함유 패취 | |
| KR101764929B1 (ko) | 셀레길린-함유 접착 제제 | |
| KR102710072B1 (ko) | 장기 투여용 리바스티그민 패취 | |
| WO2023062201A1 (en) | Transdermal therapeutic system for the transdermal administration of tizanidine | |
| WO2023144276A1 (en) | Transdermal therapeutic system for the transdermal administration of selexipag | |
| HK1187247A (en) | Transdermal therapeutic system for administering an active substance | |
| HK1187247B (en) | Transdermal therapeutic system for administering an active substance | |
| MXPA06000779A (en) | Transdermaltherapeutic system containing a pramipexol active agent |